Treatment and/or Interventions for Benign Prostatic Hyperplasia (BPH)
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Governs medical necessity and prior authorization criteria for selected minimally invasive and surgical BPH treatments for HUSKY Health (Connecticut Medicaid) providers seeking coverage for members.
No material clinical or coverage changes in this revision.
Coverage Criteria for BPH Treatments
Temporarily implanted nitinol device (CPT 53865, 53866)
Covered when ALL of the following are met
CPT codes 53865 and 53866
Transurethral waterjet ablation (Aquablation) (CPT 52597)
Covered when ALL of the following are met (authorization ONCE per lifetime)
CPT code 52597
Aquablation (transurethral waterjet ablation; CPT 52597) is not appropriate for members who meet any of the exclusion conditions listed in the coverage criteria. Specifically, Aquablation should not be performed for members with a body mass index of ≥42, those with an active infection such as a urinary tract infection or prostatitis, or members who cannot safely stop anticoagulant or antiplatelet therapy in the perioperative period. Additionally, Aquablation is excluded for individuals with a known or suspected diagnosis of prostate cancer or a prostate specific antigen (PSA) level of >10 ng/mL.
Other exclusion conditions that preclude Aquablation include a damaged external urinary sphincter; a clinically significant urethral stricture, meatal stenosis, or bladder neck contracture; and coexisting bladder pathology such as bladder cancer, neurogenic bladder, bladder calculus, or a clinically significant bladder diverticulum. Providers must confirm the absence of these conditions when documenting medical necessity for Aquablation.
Drug‑coated balloon catheter systems (for example, Optilume; CPT 52443) are considered experimental/investigational and are therefore NOT medically necessary for the treatment of BPH. The policy cites insufficient evidence in peer‑reviewed published literature to support the safety and clinical efficacy of these devices for all indications.
Coding and Clinical Thresholds
| 52443 | Examination of urethra and bladder with incision of opening of prostate gland and drug delivery using endoscope. |
| 52597 | Transurethral robotic-assisted waterjet resection of prostate, including intraoperative planning, ultrasound guidance, control of postoperative bleeding, complete, including vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy, when performed. |
| 53865 | Cystourethroscopy with insertion of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate. |
| 53866 | Catheterization with removal of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate. |
| 55881 | Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation (more than one physician). |
| 55882 | Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed (one physician). |
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required for iTind and Aquablation
Prior authorization is required for the temporarily implanted nitinol device (CPT 53865, 53866) and transurethral waterjet ablation (CPT 52597). Requests will be reviewed under the surgical prior authorization procedures in effect for HUSKY Health prior to the effective date specified in the guideline.
Conservative therapy (≥3 months) required for Aquablation
For Aquablation (CPT 52597), documentation must demonstrate failure, contraindication, or intolerance to conventional medical therapy (for example: alpha blocker, PDE5 inhibitor, finasteride/dutasteride) for at least three months before the procedure will meet coverage criteria.
Required submission materials for authorization
Submit a fully completed authorization request through the online web portal and include treating provider documentation written within the past three months that supports medical necessity per the Clinical Guideline.
- Online authorization request fully completed via web portal
- Treating provider documentation dated within the past 3 months that addresses the Clinical Guideline criteria
Authorization is not a guarantee of payment
An approved authorization reflects medical necessity at the time of the request but is not a guarantee of payment; lack of active coverage, benefits, or applicable policy at the time of service may result in claim denial.
- Authorization does not ensure payment if the member lacks active coverage or applicable benefits at time of service
- Coverage determinations are case-specific and payment is subject to policy terms and eligibility
Background on Benign Prostatic Hyperplasia (BPH)
Benign prostatic hyperplasia (BPH) is a common condition in men that can produce a spectrum of lower urinary tract symptoms (LUTS). Typical LUTS include urinary retention, increased frequency, urgency, and hesitancy, which can negatively affect quality of life. Several minimally invasive and surgical treatment options exist to relieve obstruction and symptoms, including temporarily implanted nitinol devices, transurethral waterjet ablation (Aquablation), drug‑coated balloon systems, and transurethral ultrasound ablation; coverage and utilization depend on individual clinical assessment and documented medical necessity.
Definitions and Program Scope
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.